| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PDCD5 |
| Uniprot No | O14737-1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-125aa |
| 氨基酸序列 | MADEELEALRRQRLAELQAKHGDPGDAAQQEAKHREAEMRNSILAQVLDQ SARARLSNLALVKPEKTKAVENYLIQMARYGQLSEKVSEQGLIEILKKVS QQTEKTTTVKFNRRKVMDSDEDDDY |
| 预测分子量 | 14 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PDCD5重组蛋白的模拟参考文献示例(仅供格式参考，非真实文献)：
1. **《PDCD5重组蛋白促进肿瘤细胞凋亡的机制研究》** - 作者：李明等
摘要：研究通过大肠杆菌表达系统成功纯化PDCD5重组蛋白，并发现其能通过激活caspase通路增强化疗药物诱导的肿瘤细胞凋亡。
2. **《重组PDCD5蛋白对急性白血病细胞分化的调控作用》** - 作者：王华等
摘要：实验证明PDCD5重组蛋白通过下调Bcl-2表达，促进急性髓系白血病细胞分化，为靶向治疗提供理论依据。
3. **《PDCD5蛋白与p53相互作用增强DNA损伤修复的分子机制》** - 作者：张伟等
摘要：利用重组PDCD5蛋白揭示其与p53蛋白协同作用，通过稳定p53蛋白增强细胞对DNA损伤的响应效率。
4. **《PDCD5重组蛋白在类风湿性关节炎模型中的抗炎效应》** - 作者：陈芳等
摘要：动物实验表明PDCD5重组蛋白通过抑制NF-κB通路减轻关节炎症，提示其在自身免疫疾病中的潜在治疗价值。
(注：以上为模拟内容，实际文献需通过PubMed、CNKI等学术平台检索核实。)
**Background of PDCD5 Recombinant Protein**
PDCD5 (Programmed Cell Death 5), initially identified as TFAR19 (TF-1 cell apoptosis-related gene 19), is a highly conserved protein implicated in the regulation of apoptosis and cellular stress responses. Discovered in the late 1990s, PDCD5 is ubiquitously expressed across tissues and plays a critical role in enhancing apoptosis by stabilizing the tumor suppressor p53. promoting its translocation to the nucleus, and facilitating DNA damage-induced cell death. Unlike many apoptosis-related proteins, PDCD5 is unique in its ability to amplify pro-apoptotic signals, making it a potential therapeutic target in cancers characterized by defective apoptosis.
Structurally, PDCD5 is a 14-15 kDa protein comprising 125 amino acids, with conserved N- and C-terminal domains critical for its functional interactions. Its recombinant form is typically produced using *E. coli* or mammalian expression systems, ensuring proper folding and post-translational modifications. Recombinant PDCD5 retains bioactivity, enabling its use in research to elucidate mechanisms of apoptosis, autophagy, and immune regulation.
In disease contexts, PDCD5 expression is frequently downregulated in malignancies, correlating with poor prognosis. Preclinical studies highlight recombinant PDCD5 as a promising adjuvant in cancer therapy, sensitizing tumor cells to chemotherapy and radiotherapy by restoring apoptotic pathways. Additionally, it shows potential in autoimmune and neurodegenerative diseases by modulating immune responses and neuronal survival.
Beyond therapeutic applications, recombinant PDCD5 serves as a tool for studying protein interactions, biomarker discovery, and high-throughput drug screening. Its dual role as a regulator of cell fate underscores its significance in both basic and translational research, bridging gaps in understanding apoptosis dysregulation in human diseases.
×
